Abbott has received CE Mark for its minimally invasive tricuspid heart valve repair device, TriClip Transcatheter Tricuspid Valve Repair System, making it available for treating tricuspid regurgitation (TR) in Europe.

The clip-based therapy, called TriClip G4, is a non-surgical heart valve repair option for TR treatment which allows doctors to customise valve repair according to patient anatomy.

TriClip possesses an accurate and steady delivery system made specifically for navigating the right side of the heart.

It is transported to the heart using a catheter inserted through the femoral vein in the leg and clips together parts of the tricuspid valve leaflets to reduce the backflow of blood.

As TriClip has a differentiated delivery system made for this valve and a steerable guiding catheter system, clinicians can independently clutch and efficiently clip leaflets of the valve to decrease regurgitation.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The device has two new clip sizes and a total of four sizes available, which allows clinicians to customise the device according to patient anatomy.

Abbott structural heart business senior vice-president Mike Dale said: “TR is considered the most undertreated valve issue and our newest generation device to address it is the result of our unwavering commitment to restore health and improve the quality of life for patients with structural heart disease.

“Our novel TriClip therapy offers the best possible outcomes for people suffering from a debilitating condition and gives doctors even more options for customising repair of this complex anatomy.”

According to data from the Triluminate CE Mark study of TriClip, sustained symptomatic improvement, reduced TR severity and betterment in functional status were observed, all of which indicate the benefits of the therapy. The study also validated TriClip as a safe and durable treatment option for high-risk patients with symptomatic moderate or greater TR.